| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
2e-06 |
| mRNA |
Axitinib |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
5e-06 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
2e-05 |
| mRNA |
AZD-2281 |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
2e-05 |
| mRNA |
tivozanib |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
2e-05 |
| mRNA |
navitoclax:pluripotin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.15 |
4e-05 |
| mRNA |
Mitomycin-C |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
5e-05 |
| mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
5e-05 |
| mRNA |
barasertib |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
8e-05 |
| mRNA |
alisertib |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.0002 |